PDF(604 KB)
Effect of phenytoin and levetiracetam on busulfan blood concentration in children undergoing hematopoietic stem cell transplantation
Shi-Xi XU, Guang-Ting ZENG, Jing-Yu WANG, Shu-Lan LIU, Jing LIU, Bo-Yan DENG, Ji-Ming LUO, Jie LIN, An-Fa WANG
Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (11) : 1378-1383.
PDF(604 KB)
PDF(604 KB)
Effect of phenytoin and levetiracetam on busulfan blood concentration in children undergoing hematopoietic stem cell transplantation
Objective To study the effect of prophylactic phenytoin (PHT) or levetiracetam (LEV) on busulfan (BU) blood concentration in children undergoing hematopoietic stem cell transplantation. Methods Pediatric patients conditioned with BU plus cyclophosphamide and fludarabine at the First People's Hospital of Chenzhou from September 2023 to February 2025 were retrospectively included. Patients were grouped by prophylactic antiepileptic regimen into PHT (n=24) and LEV (n=26). BU blood concentrations at the end of infusion (0 hour) and at 1, 2, and 4 hours post-infusion were compared between groups. Results At 0 hour post-infusion, BU blood concentrations did not differ significantly between groups (P>0.05). At 1, 2, and 4 hours post-infusion, BU blood concentrations were higher in the LEV group than in the PHT group (P<0.05). The area under the concentration-time curve from 0 to ∞ (AUC0-∞) was greater in the LEV group (P<0.001), and the attainment rate of AUC0-∞ was higher in the LEV group than in the PHT group (73% vs 21%, P<0.001). No significant differences were observed between groups in time to hematopoietic engraftment or in the incidence of BU-related adverse drug reactions (P>0.05). Conclusions Compared with PHT, LEV prophylaxis is associated with higher BU blood concentration and a higher AUC0-∞ attainment rate. There is no observed difference in BU efficacy or safety between PHT and LEV.
Busulfan / Phenytoin / Levetiracetam / Therapeutic drug monitoring / Drug interaction / Hematopoietic stem cell transplantation / Child
| [1] |
冯安华, 施继敏, 傅华睿, 等. 异基因造血干细胞移植治疗Shwachman-Diamond综合征: 3例报告及文献复习[J]. 中华血液学杂志, 2024, 45(7): 689-693. PMCID: PMC11388119. DOI: 10.3760/cma.j.cn121090-20240107-00009 .
|
| [2] |
|
| [3] |
|
| [4] |
张建华, 张傲利, 董春霞, 等. 应用改良BU/CY方案预处理联合自体外周血造血干细胞移植治疗青年中、低危急性髓系白血病疗效观察[J]. 中国实验血液学杂志, 2019, 27(2): 360-364. DOI: 10.19746/j.cnki.issn1009-2137.2019.02.008 .
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
U.S. Food and Drug Administration. Otsuka America Pharmaceutical, Inc. busulfan injection[EB/OL]. (2020-03)[2023-12].
|
| [12] |
夏凡, 刘明红, 于迪, 等. 静脉滴注白消安致急性精神异常[J]. 中国医院药学杂志, 2020, 40(17): 1902-1903. DOI: 10.13286/j.1001-5213.2020.17.21 .
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
王磊, 李梦, 张建平, 等. 白消安为主的不同预处理方案在异基因造血干细胞移植中应用的短期疗效和安全性[J]. 中国新药与临床杂志, 2022, 41(6): 357-362. DOI: 10.14109/j.cnki.xyylc.2022.06.08 .
|
| [22] |
中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 中华肝脏病杂志, 2023, 31(4): 355-384. DOI: 10.3760/cma.j.cn501113-20230419-00176-1 .
|
| [23] |
王伊娜, 左力, 燕宇. 《抗肿瘤药物治疗期间肾损伤管理临床实践指南(2022)》解读(三):抗肿瘤药物治疗患者的肾功能评估(第2部分)[J]. 药物不良反应杂志, 2024, 26(7): 385-389. DOI: 10.3760/cma.j.cn114015-20240507-00308 .
|
| [24] |
冯新颖, 吴云娇, 李佳朋, 等. 白消安个体化给药的群体药代动力学研究现状[J]. 中国临床药理学杂志, 2018, 34(24): 2884-2888. DOI: 10.13699/j.cnki.1001-6821.2018.24.023 .
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
所有作者均声明不存在利益冲突。